We were formed in 2017 to tackle market inefficiencies that disrupt access to healthcare. Today, our guarantees are helping to increase access to healthcare products in underserved communities.
MedAccess was established in November 2017. We were originally formed as The Credit Facility for Access to Medicines, in response to ongoing concerns within the global health community that access to medical supplies in low- and middle-income countries was being impeded by market inefficiencies.
MedAccess was founded by British International Investment (BII), the UK’s development finance institution, with support from the Department for International Development (now replaced by the Foreign, Commonwealth & Development Office (FCDO)) and the Clinton Health Access Initiative (CHAI). MedAccess is a wholly-owned subsidiary of BII.
$200m capital authorised by British International Investment (BII) in preparation for MedAccess’ incorporation.
MedAccess formally incorporated. Michael Anderson begins work as CEO.
Nigel Keen appointed Board Chair. First $100 million of paid-in capital issued by BII.
Launch of volume guarantee for Hologic’s Panther viral load testing platform announced at AIDS 2018 conference, in partnership with the Clinton Health Access Initiative (CHAI).
Launch of volume guarantee for BASF’s Interceptor® G2 mosquito nets announced at Global Fund replenishment event, in partnership with the Bill & Melinda Gates Foundation.
BII pays in further $100 million capital, taking MedAccess’ capitalisation to $200 million.
Launch of procurement guarantee for UNICEF to accelerate procurement of essential COVID-19 and non-COVID-19 supplies.
UNICEF procurement guarantee for essential COVID-19 and non-COVID-19 products extended by one year.
MedAccess’ 2021-2025 strategy approved by the Board.
Launch of volume guarantee to catalyse access to Macleods’ 3HP latent tuberculosis treatment, in partnership with CHAI and Unitaid.
Launch of innovative financing agreement with Gavi and GSK to support continued production of RTS,S malaria vaccine antigen ahead of key policy and funding decisions. MedAccess comes off risk in December when positive policy and funding decisions are announced.
Launch of volume guarantee to catalyse access to SD Biosensor’s dual HIV-syphilis rapid diagnostic test, in partnership with CHAI.
Launch of procurement guarantee with the Open Society Foundations to help meet country demand for COVID-19 vaccines via COVAX’s cost-sharing mechanism.
Launch of volume guarantee to catalyse access to Wondfo’s HIV self-test, in partnership with CHAI.
Launch of volume guarantee to catalyse access to SD Biosensor’s G6PD testing devices and strips, in partnership with PATH.
Professor Helen Rees OBE appointed Board Chair.
Sign up for our quarterly updates to find out more about how our work is making healthcare products more affordable and accessible.
